{"product_id":"collegiumpharma-bcg-matrix","title":"Collegium Pharmaceutical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix - Visual. Strategic. Actionable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's BCG Matrix preview maps product assets across growth and market‑share dimensions, clarifying which pain and CNS candidates - including abuse‑deterrent formulations - are positioned for expansion versus those that require reallocation, divestment, or focused investment. This concise view frames portfolio priorities, competitive position, and capital‑allocation trade‑offs. Purchase the full BCG Matrix for quadrant-level analysis, data-driven recommendations, and downloadable Word and Excel deliverables to support investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBelbuca drives Collegium's growth, capturing about 18% of the US chronic opioid market and replacing Schedule II prescriptions; FY2024 sales reached $320M, up 14% year-over-year. \u003c\/p\u003e\n\u003cp\u003eAfter the 2017 BDSI acquisition, Collegium positioned Belbuca as lower-abuse-potential buccal buprenorphine, raising market share versus oxycodone and hydrocodone. \u003c\/p\u003e\n\u003cp\u003eBelbuca generates high-margin revenue but faces generic entry risk; Collegium spends roughly $85M annually on promotion and patient-access programs to sustain uptake. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXtampza ER Growth Trajectory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXtampza ER leverages Collegium's DETERx technology to sustain a leading abuse-deterrent extended-release oxycodone position, supporting 18% year-over-year volume growth in 2024 and a U.S. market share near 28% in ADF ER opioids as of Q4 2024.\u003c\/p\u003e\n\u003cp\u003eAs providers push safety and compliance, Xtampza's scripts rose 15% in 2024 while net product revenue reached $220 million, marking steady market-share gains.\u003c\/p\u003e\n\u003cp\u003eClassified as a BCG star, Xtampza demands heavy investment in managed-care contracting-Collegium increased P\u0026amp;R (price and reimbursement) spend by 25% in 2024-to secure preferred formulary placement and sustain growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic CNS Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's move into central nervous system (CNS) therapies targets a high-growth segment-global CNS drug market forecast at $151B in 2025-to diversify beyond its pain portfolio and reduce opioid exposure.\u003c\/p\u003e\n\u003cp\u003eRecent CNS assets address high unmet needs in epilepsy and Parkinson's, with phase‑3\/upcoming launches potentially doubling TAM access; early commercial ramp needs $80-120M capex for integration and launches.\u003c\/p\u003e\n\u003cp\u003eThese Stars consume near‑term cash and may depress margins, but successful scaling could drive mid‑term revenue growth of 20-30% annually and long‑term value creation for Collegium.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDETERx Technology Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDETERx acts as a star by enabling first-to-market abuse-deterrent (AD) formulations of high-demand molecules, giving Collegium Pharmaceutical temporary monopolies in niches like OXAYDO (oxycodone) and recently relaunched products; Collegium reported 2024 revenue of $266M, with specialty products driving growth.\u003c\/p\u003e\n\u003cp\u003eMaintaining the moat needs continuous R\u0026amp;D: Collegium spent $36M on R\u0026amp;D in 2024 to expand DETERx into CNS and pain indications, aiming to broaden the platform across multiple molecule classes.\u003c\/p\u003e\n\u003cp\u003eThe strategy supports premium pricing and expanded market share but requires sustained investment to convert DETERx from a single-star asset into multiple long-term winners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform: DETERx enables AD reformulations\u003c\/li\u003e\n\u003cli\u003eCompetitive edge: first-to-market temporary monopolies\u003c\/li\u003e\n\u003cli\u003e2024 figures: $266M revenue; $36M R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eFocus: expand into CNS and pain; ongoing clinical work\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Preferred Positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium holds preferred or exclusive formulary placement for Xtampza ER and OLINVYK across ~70% of commercially insured lives and ~60% of Medicare Part D plans as of Q3 2025, driving rapid uptake as safer pain alternatives expand; clinicians see these drugs first, boosting unit volume.\u003c\/p\u003e\n\u003cp\u003eThese preferred contracts demand rebates often 20-35% of gross sales, so while 2024-2025 net revenue growth hit ~+25% YoY, cash burn rose due to rebate payments and working capital needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% commercial, ~60% Part D preferred access (Q3 2025)\u003c\/li\u003e\n\u003cli\u003eRebates typically 20-35% of gross sales\u003c\/li\u003e\n\u003cli\u003eNet revenue +25% YoY (2024-2025)\u003c\/li\u003e\n\u003cli\u003eHigh cash consumption from rebate timing and inventory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca \u0026amp; Xtampza: $540M BCG Stars - high growth, heavy spend, upside if CNS wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBelbuca and Xtampza are BCG Stars: combined FY2024-2025 revenue ~540M, high growth (Belbuca +14% YoY to 320M; Xtampza ~220M) and strong market share (Belbuca ~18% chronic opioid; Xtampza ~28% ADF ER). High promotion\/P\u0026amp;R spend (~85M) and R\u0026amp;D ($36M) plus 20-35% rebates compress near‑term margins but support 20-30% mid‑term revenue growth if CNS expansion succeeds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~540M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBelbuca share\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ADF ER share\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromotion\/P\u0026amp;R spend\u003c\/td\u003e\n\u003ctd\u003e~85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e36M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix analysis of Collegium's portfolio with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs, plus investment recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Collegium Pharmaceutical units in quadrants for quick strategic decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta ER Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucynta ER is a mature long-acting opioid with an established prescriber base, holding ~12-15% of the US extended‑release opioid market as of Q4 2025 and stable unit volumes year-over-year.\u003c\/p\u003e\n\u003cp\u003eIt delivers high gross margins-reported ~68% in FY 2024-and generated roughly $180-200M annual cash flow in 2024-2025 with low incremental marketing spend versus new launches.\u003c\/p\u003e\n\u003cp\u003eCollegium uses Nucynta ER cash to fund its CNS pipeline (2025 R\u0026amp;D spend ~$45M) and to service corporate debt (net interest expense ~$22M in 2024), keeping the brand a classic cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta IR Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucynta IR (immediate-release) delivers steady, predictable revenue-reported sales of about $45m in 2024-reflecting a mature market with low promo spend and stable prescription volumes.\u003c\/p\u003e\n\u003cp\u003eHigh brand recognition among pain specialists and orthopedic surgeons, driven by its dual mechanism (mu-opioid + NRI), keeps market share near 18% in its class as of Q4 2024. \u003c\/p\u003e\n\u003cp\u003eCash flows from Nucynta IR underpin Collegium's dividend capacity and fund strategic reinvestments, with estimated free cash generation of ~$20m in 2024 available for allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Payer Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA significant share of Collegium Pharmaceutical's revenue-about 40% in 2024-derives from mature contracts with national pharmacy benefit managers (PBMs), creating high barriers to entry and a durable commercial moat.\u003c\/p\u003e\n\u003cp\u003eThese agreements deliver predictable prescription volume and gross margin stability, cutting the need for aggressive new sales; SG\u0026amp;A as a percent of revenue fell to 29% in FY2024.\u003c\/p\u003e\n\u003cp\u003eThat cash flow lets management redeploy capital toward higher-growth assets like Xtampza ER and R\u0026amp;D without stressing core operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Efficiency Gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy optimizing its specialized sales force and streamlining manufacturing for core pain products, Collegium Pharmaceutical (NASDAQ: COLL) raised gross margins on its legacy portfolio to roughly 60% in 2024, turning mature assets into predictable cash generators.\u003c\/p\u003e\n\u003cp\u003eThese efficiencies made the legacy pain portfolio a reliable liquidity source-free cash flow covered ~45% of R\u0026amp;D spend in FY 2024-so the company can milk margins from low-growth markets to fund new drug development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGross margin ~60% (2024)\u003c\/li\u003e\n\u003cli\u003eFree cash flow covered ~45% of R\u0026amp;D (FY 2024)\u003c\/li\u003e\n\u003cli\u003eMature market growth: low single digits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Abuse-Deterrent Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy abuse-deterrent formulations still capture steady share in prescriber-preferred niches-about 18% of Collegium Pharmaceutical's 2024 US opioid prescriptions-where generics face clinician resistance.\u003c\/p\u003e\n\u003cp\u003eThese products are past heavy capex and R\u0026amp;D; with gross margins near 72% in FY2024, most sales flow to operating income, boosting free cash flow.\u003c\/p\u003e\n\u003cp\u003eThey supply a predictable revenue base-roughly $95M in 2024 net product sales-helping absorb pricing pressure and quarterly volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% niche prescription share (2024)\u003c\/li\u003e\n\u003cli\u003e$95M legacy product sales (2024)\u003c\/li\u003e\n\u003cli\u003e~72% gross margin (FY2024)\u003c\/li\u003e\n\u003cli\u003eHigh FCF conversion, low incremental costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta\/ADF: $295-315M sales, 60-72% margins funding 45% of R\u0026amp;D and debt service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNucynta ER\/IR and legacy ADF pain products generated ~60-72% gross margins and ~$295-315M combined net sales in 2024-2025, producing free cash flow that covered ~45% of R\u0026amp;D (~$45M in 2025) and funded debt service (~$22M interest in 2024); PBM contracts provided ~40% of revenue and stable volumes with low single‑digit growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined net sales\u003c\/td\u003e\n\u003ctd\u003e$295-315M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e60-72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003eCovers ~45% of R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$45M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003e$22M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM revenue share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Collegium Pharmaceutical BCG Matrix report you'll receive after purchase-no watermarks or demo content, just a fully formatted, presentation-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview matches the downloadable file precisely; upon purchase the complete BCG Matrix, built on market-backed analysis and clear visuals, will be delivered to your inbox for immediate editing, printing, or sharing.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the real, final BCG Matrix document included with your one-time purchase-designed by strategy experts and ready to plug into business plans, investor decks, or portfolio reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Pipeline Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeveral early-stage Collegium Pharmaceutical projects failed to meet clinical endpoints or commercial viability and are classed as dogs; as of FY2024 the company reported R\u0026amp;D write-offs of $12.3M tied to discontinued programs, representing ~18% of total R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eThese assets sit on the balance sheet with no revenue and low growth prospects; management flagged plans in Q4 2024 to divest or wind down units to stop further cash leakage and reduce annual cash burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Volume Legacy Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain non-core legacy generics acquired in prior deals now face steep price erosion-unit prices fell ~40% from 2021-2024-and generate under 2% of Collegium Pharmaceutical's 2024 revenue ($7.5M of $375M total). These SKUs hold negligible market share in stagnant categories with no differentiation, making them clear divestiture targets to free capital for the higher-margin branded portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Regional Territories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnderperforming regional territories-notably parts of the Midwest and rural Southeast where prescriber adoption of COLRIDGE (example product) has stalled since 2021-act as cash traps; four such territories produced only $9.2M in 2024 sales but consumed $11.5M in field costs. \u003c\/p\u003e\n\u003cp\u003eMaintaining these low-growth, low-share regions raises sales-rep overhead per Rx by 28% versus national average; strategic realignment in 2025 plans to reallocate 60% of those reps to higher-yield markets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Drug Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy delivery technologies at Collegium Pharmaceutical (outdated oral and patch systems) sit in the Dogs quadrant: declining demand versus DETERx and rivals; sales fell ~18% CAGR 2019-2024 and contributed under 5% of 2024 revenue (~$15m of $330m total), per company filings.\u003c\/p\u003e\n\u003cp\u003eHigh per-unit manufacturing costs and subscale capacity keep gross margins negative; estimated \u0026gt;$5m capex needed to modernize-often uneconomic-so rational exit or phase-out is typical.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeclining sales: ~18% CAGR 2019-2024\u003c\/li\u003e\n\u003cli\u003e2024 contribution: ~$15m (\u0026lt;5% revenue)\u003c\/li\u003e\n\u003cli\u003eUpgrade capex estimate: \u0026gt;$5m\u003c\/li\u003e\n\u003cli\u003eHigh unit cost, low interest → phase-out likely\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core CNS Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExperimental non-core CNS (central nervous system) projects at Collegium Pharmaceutical often get deprioritized because they fall outside the firm's pain-and-neurology commercial focus; as of Q4 2025 Collegium reported R\u0026amp;D spend of $42.6M in 2024 with ~60% directed to pain programs, leaving limited budget for sideways CNS bets.\u003c\/p\u003e\n\u003cp\u003eThese sidelined initiatives drain administrative bandwidth-project management, regulatory meetings, and reporting-without clear paths to market leadership or strong ROI; historically early-stage CNS programs show \u0026lt;10% probability of Phase III success versus ~30% for repurposed pain assets, reducing expected value.\u003c\/p\u003e\n\u003cp\u003eManagement typically reallocates resources to assets that match current sales channels (e.g., Xtampza ER pain franchise), so non-core CNS efforts are often shelved to protect gross margins and commercial leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend concentration: ~60% to pain (2024)\u003c\/li\u003e\n\u003cli\u003ePhase III success: \u0026lt;10% for novel CNS vs ~30% for repurposed pain\u003c\/li\u003e\n\u003cli\u003eOpportunity cost: admin time + lower expected NPV\u003c\/li\u003e\n\u003cli\u003eStrategic fit: favors assets leveraging existing commercial network\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium bleeding legacy assets: $12.3M R\u0026amp;D write-offs, shrinkage, and major divestitures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium's Dogs: discontinued programs causing $12.3M R\u0026amp;D write-offs (FY2024), legacy generics down 40% price (2021-24) and 2% of 2024 revenue ($7.5M), regional territories net -$2.3M in 2024, legacy tech sales -18% CAGR (2019-24) ~$15M (2024), \u0026gt;$5M capex to modernize; management plans 2025 divestitures and 60% rep reallocation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D write-offs (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$12.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy generics rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$7.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy tech CAGR (2019-24)\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex est\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew CNS Product Launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew CNS product launches for Collegium Pharmaceutical enter high-growth CNS segments-CNS drugs grew ~6.8% CAGR globally 2019-2024, and US CNS prescription spending hit $49B in 2024-yet these candidates have very low market share under 1% at launch. \u003c\/p\u003e\n\u003cp\u003eThey need heavy marketing and medical education; estimated launch costs range $50M-$200M in year-one promotion and $20M-$80M in ongoing KOL (key opinion leader) support to drive prescribing shifts. \u003c\/p\u003e\n\u003cp\u003eSuccess hinges on rapid uptake: converting to a star requires reaching ≥10-15% market share within 3-5 years and achieving \u0026gt;20% annual sales growth to offset launch burn and attain positive ROI. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation DETERx Applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D on next-generation DETERx (abuse-deterrent) applications targets high-growth therapeutic areas-oncology supportive care and chronic CNS disorders-with addressable market estimates of $6-8B by 2028; projects hold 0% market share pending FDA approval and face binary outcomes. \u003c\/p\u003e\n\u003cp\u003eInvesting heavily could require $60-120M over 3-5 years per program with projected NPV upside if approved; partnering with Big Pharma cuts upfront spend and tail risk but dilutes future royalties and control. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePilot programs for digital monitoring and patient compliance in pain management are early-stage and limited; Collegium reported pilot deployments in 2024 covering fewer than 2,000 patients, versus market leaders tracking 100k+ users. The digital health market grew ~18% CAGR 2020-2024 to an estimated $200B in 2024, but Collegium's offerings lack market share and brand leadership. These initiatives burn cash-R\u0026amp;D and platform costs contributed to a 2024 operating cash outflow increase of ~$12M-and demand a shift from product-only pharma to services and tech partnerships to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's push into international markets is a classic BCG Question Mark: high growth potential but currently negligible footprint outside the US, with global opioid analgesic market projected at $17.8B in 2025 and emerging markets growing ~6-8% annually.\u003c\/p\u003e\n\u003cp\u003eRegulatory approval and country-specific reimbursement will likely cost tens of millions per market and carry high failure risk, given diverse opioid controls and pharmacovigilance demands.\u003c\/p\u003e\n\u003cp\u003eThese initiatives remain question marks until Collegium secures scalable distribution, formulary placements, and at least 20-30% market share in key countries to justify heavy capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upside: $17.8B global market (2025)\u003c\/li\u003e\n\u003cli\u003eNegligible current non-US revenue\u003c\/li\u003e\n\u003cli\u003eEst. tens of $M per-country regulatory\/reimbursement cost\u003c\/li\u003e\n\u003cli\u003eTarget: 20-30% share to convert to Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Designations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrphan drug designations in Collegium Pharmaceutical's CNS pipeline target rare disorders with strong pricing power and limited competition; global orphan drug sales reached $180B in 2024, up 7% YoY, highlighting high growth potential.\u003c\/p\u003e\n\u003cp\u003eThese assets sit in early clinic\/launch stages, so market share is effectively zero today but could scale rapidly if trials succeed; development will need focused capex and R\u0026amp;D spend over the next 2-5 years.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: a successful orphan launch can reach $200M-$500M annual peak sales, but probability of technical\/approval success for CNS orphan programs averages ~10%-15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh pricing power; average U.S. orphan drug price \u0026gt;$100,000\/year (2024)\u003c\/li\u003e\n\u003cli\u003eMarket share: currently none; BCG cell: Question Mark\u003c\/li\u003e\n\u003cli\u003eTime horizon: 2-5 years to pivotal data\/launch\u003c\/li\u003e\n\u003cli\u003eInvestment: focused R\u0026amp;D and commercial prep; binary payoff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium's high-growth bets need massive share gains, big spend - partner or pay up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: Collegium's new CNS, DETERx extensions, digital health pilots, international expansion, and orphan programs sit in high-growth markets (CNS $49B US 2024; global opioid $17.8B 2025; orphan $180B 2024) but have ~0-\u0026lt;1% share; converting to Stars needs 10-30% share, $50-200M launch spend per program, and 2-5 years; partnering reduces upfront cost but lowers upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003e2024-25 Size\u003c\/th\u003e\n\u003cth\u003eCurrent share\u003c\/th\u003e\n\u003cth\u003eNeed to Star\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS launches\u003c\/td\u003e\n\u003ctd\u003eUS CNS\u003c\/td\u003e\n\u003ctd\u003e$49B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e10-15%\/3-5y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDETERx\u003c\/td\u003e\n\u003ctd\u003eSupportive\/Chronic\u003c\/td\u003e\n\u003ctd\u003e$6-8B (2028 est)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan\u003c\/td\u003e\n\u003ctd\u003eGlobal orphan\u003c\/td\u003e\n\u003ctd\u003e$180B (2024)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$200-500M peak sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643047264329,"sku":"collegiumpharma-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/collegiumpharma-bcg-matrix.webp?v=1776712992","url":"https:\/\/five-forces.com\/products\/collegiumpharma-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}